Diisopropylethylamine → 7-methoxy-3-{-1-[6-(7-methyl-3H-benzimidazol-5-yloxy)-pyrimidin-4-yl]-piperidin-4-yl}-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one
Reaktionsgleichung
[CH3:1][O:2][C:3]1[CH:4]=[CH:5][C:6]2[NH:12][C:11](=[O:13])[N:10]([CH:14]3[CH2:19][CH2:18][NH:17][CH2:16][CH2:15]3)[CH2:9][CH2:8][C:7]=2[CH:20]=1.Cl[C:22]1[N:27]=[CH:26][N:25]=[C:24]([O:28][C:29]2[CH:30]=[C:31]([CH3:38])[C:32]3[N:36]=[CH:35][NH:34][C:33]=3[CH:37]=2)[CH:23]=1.CCN(C(C)C)C(C)C>CN(C=O)C>[CH3:1][O:2][C:3]1[CH:4]=[CH:5][C:6]2[NH:12][C:11](=[O:13])[N:10]([CH:14]3[CH2:19][CH2:18][N:17]([C:22]4[CH:23]=[C:24]([O:28][C:29]5[CH:30]=[C:31]([CH3:38])[C:32]6[N:36]=[CH:35][NH:34][C:33]=6[CH:37]=5)[N:25]=[CH:26][N:27]=4)[CH2:16][CH2:15]3)[CH2:9][CH2:8][C:7]=2[CH:20]=1Komponenten
5
Edukt 3
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
47 mg (0.17 mmol) 7-methoxy-3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one, 45 mg (0.17 mmol) 6-(6-chloro-pyrimidin-4-yloxy)-4-methyl-1H-benzimidazole and 0.06 mL (0.34 mmol) DIPEA were combined in 2.0 mL DMF and stirred for 48 h at RT. The reaction mixture was purified by preparative HPLC-MS. The product-containing fractions were combined and the acetonitrile was evaporated down. The residue was made alkaline with 4N aqueous sodium hydroxide solution, the precipitate formed was suction filtered, washed with water and dried under HV.
Aufarbeitung
- customThe reaction mixture was purified by preparative HPLC-MS
- customthe acetonitrile was evaporated down
- customthe precipitate formed
- filtrationfiltered
- washwashed with water
- customdried under HV
Quellen und Nachweise
- ORD-Eintrag
- ord-c86fa41fcbdf40999ffca6ddcb89e204
- Quelldatensatz
- uspto-grants-2015_02
- Patentnummer
- US08952014B2
Notizen zur Reaktion
Wird geladen…